Logo Sangui

Sangui BioTech GmbH press releases:

Sangui BioTech:
  • Sales of USD 63,429 in the first nine month

Witten, May, 14 2019:

In the first nine months of fiscal year 2019 (to 30/06/2019) Sangui BioTech International Inc. achieved revenues from royalty income of USD 63,429. In the same period of the previous year the comparable revenue amounted to USD 65,273. Due to only slightly lower revenues of the wound spray Granulox, the resulting royalty income in the first nine month of the year remained at the level of the same period of the previous year.

While royalty income in the first half of the year were still higher than in the previous year, royalty income in the third quarter were USD 2,129 lower than in the same period of the previous year. Despite the strong end-of-year business in 2018, royalty income in the first three quarters therefore declined by USD 1,844 or 3% compared to the previous year.

As operating expenses increased USD 48,062 or 20% to USD 291,214 during the period, nine month operating loss increased USD 49,862 to USD 227,785 from the prior year. The operating loss for the third quarter of 2019, on the other hand, increased disproportionately by USD 5,352 compared to the previous year to USD 74,150.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


Sangui BioTech:
  • Patent granted to Sangui for possible Septic Shock treatment

Witten, March 06, 2019:

The European Patent Office has granted a patent for Sangui's proposed technology/treatment (SBT 102) for septic shock patients, effective March, 6, 2019*. The patent follows up on animal studies carried out by the ECCPS (Excellence Cluster Cardio-Pulmonary System**), Giessen, Germany.

The studies conducted by the ECCPS have resulted in proof-of concept data, utilizing a related technology to Sangui's unique hemoglobin oxygen carrier technology which is already successfully employed by Granulox, a medical device for treatment of chronic wounds. Granulox is distributed by Sastomed GmbH, a fully owned subsidiary of Mölnlycke Health Care GmbH.

The co-authors of the ECCPS studies, Prof. Dr. Ralph Schermuly and Prof. Dr. Ardeshir Ghofrani, come to the conclusion: “We conclude that the intraperitoneal application of SBT 102 is an innovative and effective therapy to avoid tissue hypoxemia. The restoration of intestinal oxygenation will have impact on tissue integrity and finally patient survival.”

* Subject to Opposition Period of 9 Months (Article 99 EPC).
** The ECCPS (www.eccps.de) is a joint centre of the Justus-Liebig-University Giessen, the Goethe University Frankfurt and the Max-Planck-Institute for Heart and Lung Research in Bad Nauheim in the field of heart and lung research.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


Sangui BioTech:
  • Sales of USD 55,367 in the first half-year
  • Strong year-end-business

Witten, February, 14 2019:

In the first six months of fiscal year 2019 (to 30/06/2019) Sangui BioTech International Inc. achieved revenues from royalty income of USD 55,367. In the same period of the previous year the comparable revenue amounted to USD 55,082. Due to only slightly higher revenues of the wound spray Granulox, the resulting royalty income in the first half of the year remained at the level of the same period of the previous year.

While the first quarter lagged behind the previous year, royalty income in the second quarter clearly exceeded those of the prior-year period. For example, the strong year-end business in 2018 led to a rise in second-quarter royalty income revenues of USD 5,646 or 15% compared to the previous year.

As operating expenses increased USD 44,740 or 27% to USD 208,903 during the period, first half years operating loss increased USD 44,510 to USD 153,635 from the prior year. The operating loss for the second quarter of 2019, on the other hand, increased disproportionately by USD 8,801 compared to the previous year to USD 60,137.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


pdf_download   PDF Download

Sangui BioTech News
14.05.2019

Sangui BioTech News
06.03.2019

Sangui BioTech News
14.02.2019

Sangui BioTech News
15.11.2018

Sangui BioTech News
02.10.2018

Sangui BioTech News
25.07.2018

Sangui BioTech News
03.07.2018

Sangui BioTech News
22.05.2018

Sangui BioTech News
04.05.2018

Sangui BioTech News
14.02.2018

Sangui BioTech Financials
19.01.2018

Sangui BioTech Financials
21.11.2017

Sangui BioTech News
10.11.2017

Sangui BioTech Financials
23.10.2017

Sangui BioTech News
12.07.2017

Sangui BioTech Financials
24.02.2017

Sangui BioTech Financials
12.01.2017

SastoMed sales agreements
21.12.2016

Sangui BioTech Financials
22.11.2016

SastoMed sales agreements
01.11.2016

Sangui Bio Tech International News
13.10.2016

Sangui Bio Tech International News
30.09.2016

Sangui Bio Tech International News
06.06.2016

Sangui Bio Tech International publishes preliminary figures for first half year
01.02.2016

Sluggish revenue development continues / Comprehensive cost containment program under preparation / Joachim Fleing stepped down
28.10.2015

Revenues of USD 127,000 in financial year 2015; net loss, cash burn reduced; revenues from Granulox license fees in EUR up 34.4%
29.09.2015

Positive Outlook after Weak Fourth Quarter / Cost Cutting Initiated
27.08.2015

Sangui BioTech International files S-1 Registration Statement with the SEC
26.06.2015

Practitioners present wound healing case studies under Granulox treatment
02.06.2015

Lower revenues in the third quarter
15.05.2015

Sangui BioTech International secures financial framework
of $5 million over three years
12.05.2015

Series of preclinical trials concluded successfully
18.03.2015

Revenues slightly improved in the first half of the 2015 financial year
Research and development focuses on preclinical trials
12.02.2015

SastoMed closes contracts with distribution partners in six additional markets in Eastern Europe
03.02.2015

Shareholder Letter
28.01.2015

SanguiBioTech yields revenues of over USD31,000 in Q2 2015 according to preliminary figures
28.01.2015

Revenues improved in the first quarter of the 2015 financial year
13.11.2014

Preclinical trials demonstrate: Sangui hemoglobin preparation improves oxygen supply of vital organs
11.11.2014

Sangui BioTech International officially approved as trading on OTCQB
06.11.2014

Laboratorios Silanes start marketing Granulox in Mexico
03.11.2014

SanguiBioTech yields revenues of over USD70,000 in Q1 2015 according to preliminary figures
07.10.2014

Revenues attain USD 133,000 in financial year 2014
25.09.2014

Start of preclinical trials
Target: certification of an oxygen carrier as a Class III medical product
08.08.2014

Granulox technology patent now legally binding
31.07.2014

SanguiBioTech yields revenues of around USD42,000 in Q4 2014 according to preliminary figures
29.07.2014

Oxygen Supply for Chronic Wounds Meets Enhanced Public Awareness
26.05.2014

Sangui BioTech announces results of the first nine months of its 2014 financial year
15.05.2015

Sangui, ECCPS and TransMIT start biological in vitro experiments aimed at the characterization of hemoglobin polymers
25.04.2014

Revenues slightly improved in the first half of the 2014 financial year
Research and development for new patent application, preparation of animal test continued
14.02.2014

Shareholder Letter
14.01.2014

Partner Companies in Italy, Finland and Portugal Prepare to Sell Granulox
05.12.2013

Granulox distribution rights for the UK, Ireland, USA, Canada, Australia and New Zealand granted to infirst HEALTHCARE
15.11.2013

Revenues slightly improved in the first quarter of the 2014 financial year
Research and development for new patent application, preparation of animal test
06.11.2013

Sangui BioTech GmbH and ECCPS commence with studies on curing life-threatening ischemic conditions in the body
15.10.2013

Wound management specialist dealer will distribute Granulox in Switzerland
SastoMed GmbH and Agentur Scherrer GmbH sign agreement
08.10.2013

Granulox to enter Columbian market – SastoMed signs contract with distributor Colpharma
23.09.2013

Granulox wound spray is most innovative aerosol product of the year
17.09.2013

Start of Granulox-Sales in Greece scheduled for October 31, 2013
10.09.2013

Sangui BioTech files comprehensive new patent application significantly expanding the protection of its hemoglobin formulations
04.09.2013

Wound therapeutic Granulox obtains another 18 years of patent protection for the entire European Union
13.08.2013

SastoMed gains top-class Granulox distribution partner in Southeast Europe
16.07.2013

Sangui reports increase in revenue, looking at longer Granulox market entry phase
21.05.2013

Sangui BioTech: First Step towards a European Granulox Distribution Network
BiologiQ and SastoMed Agree upon Exclusive Sales Partnership for the Benelux Countries
22.04.2013

Approval of blood additive appears possible, expedient and promising
Feasibility study available
09.04.2013

Continuous trading in Sangui shares restored in German markets
Additional listing on Berlin stock exchange
22.03.2013

BioTech company Sangui strikes a positive half year balance
Revenues grow, additional investments in marketing and sales
15.02.2013

Biotech company Sangui presents Granulox wound treatment study
05.02.2013

Biotech enterprise Sangui starts expanding internationally recording large order from Mexico
21.12.2012

Most extensive clinical study so far at Karls University in Prague shows: Granulox has positive influence on healing of leg ulcers Results to be published in issue 3/2013 of renowned medical journal
12.12.2012

Sangui patent for Production of Artificial Oxygen Carriers granted
17.10.2012

Sangui and SastoMed Complement Licensing Agreement in View of Increasing Sales Success
27.08.2012

Over 500 Customers: Granulox Sales Ahead of Planning Initial investments will have amortized by 2014 according to SastoMed / Licensing agreement will yield income for Sangui with the beginning of 2013, exponential growth expected
13.08.2012